Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest SIR-Spheres Stories

2013-10-24 12:27:11

Brazil and Argentina Remain The Most Attractive Markets For Competitors, According to Millennium Research Group TORONTO, Oct. 24, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the Latin American transcatheter embolization and occlusion (TEO) device market will exhibit strong growth through 2022. Two main factors will support market expansion: the growing Latin American economies and an increasing...

2013-10-01 08:30:03

LONDON, October 1, 2013 /PRNewswire/ -- NHS revision of Clinical Policy Commissioning Statement on SIRT will allow patients in England with metastatic colorectal cancer (mCRC) and intrahepatic cholangiocarcinoma (ICC) who may benefit from SIR-Spheres(R) microspheres to get treatment in specialist NHS centres NHS England has issued an interim Clinical Commissioning Policy Statement that updates its policy on Selective...

2013-07-24 12:28:14

LONDON, July 24, 2013 /PRNewswire/ -- NEW UK GUIDANCE SHOULD IMPROVE PATIENT ACCESS TO SIR-SPHERES(R) MICROSPHERES FOR PRIMARY LIVER CANCER The UK National Institute for Health and Clinical Excellence (NICE) has published guidance to support the routine use of SIRT (Selective Internal Radiation Therapy) for the treatment of patients with primary liver cancer.[1] This decision is good news for patients with the most-common form of...

2013-06-24 12:25:33

PARIS, June 24, 2013 /PRNewswire/ -- Launched by the Assistance Publique - Hopitaux de Paris (AP-HP) in December 2011, SARAH, a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma seeks to enroll 400 patients To date, more than 150 patients have taken part in this study PARIS (June 20, 2013) In...

2013-06-20 12:31:16

BOLOGNA, Italy, June 20, 2013 /PRNewswire/ -- Based on New Data from Multi-Centre ENRY Evaluation of 325 Patients, Authors Suggest that Radioembolisation May Be a Well-Tolerated and Effective Option for an Increasing Population of Older Patients Results of a new analysis by members of the multi-centre European Network on Radioembolisation with Yttrium-90 Resin Microspheres (ENRY), published on-line in the Journal of Hepatology, the...

2013-06-20 08:25:57

SYDNEY and WESTMINSTER, Colo., June 20, 2013 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets. The agreement will see Sirtex exclusively distribute the Surefire Medical range of products in the company's rapidly growing Asia Pacific markets including Australia. Sirtex...

2012-12-11 04:21:35

SYDNEY, December 11, 2012 /PRNewswire/ -- http://www.sirtex.com informs doctors, patients and investors about the world's most widely used and widely studied form of SIRT for all cancers in the liver Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining...

2012-10-21 19:20:07

MAGDEBURG, Germany, October 21, 2012 /PRNewswire/ -- Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a matched-pair comparison of patients with metastatic colorectal cancer predominately affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres...

2012-03-23 06:22:34

ORLANDO, March 23, 2012 /PRNewswire/ -- New Australian Data Provides Further Evidence of Survival Benefit for Radioembolisation Findings from the largest comparative multi-centre study performed to date using radioembolisation report a significantly prolonged survival benefit following SIR-Spheres microspheres in patients with treatment-refractory liver tumours from colorectal and other cancers. The results of the study were presented today at the 65th Annual Cancer...

2012-02-03 01:00:00

PARIS, February 3, 2012 /PRNewswire/ -- 'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment The start of SARAH, a new randomized controlled trial to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (SIR-Spheres(R) microspheres; Sirtex Medical...